| Revenue growth | Q4 +22% YoY; FY26 +8% (Standalone). |
|---|---|
| Margins | EBITDA profile moving from ~11% toward 20% target. |
| Order book | Secured ₹823cr multi-year mandate. |
| Demand visibility | High visibility through multi-year mandates and recurring revenues. |
Growth
Q4 FY26 Revenue grew 22% (₹472cr); Medical Devices grew 31%; API grew 17%. Full year FY26 revenue rose 8%.
Outlook
Targeting 20%+ EBITDA margins via CDMO expansion; manufacturing capacity plan for ~1000 KL; secured ₹823cr multi-year mandate.
Risks
API pricing remained volatile; FY26 PAT dropped 35% YoY to ₹66cr due to manufacturing scale-up and strategic investments.
Earnings Call filed with NSE, NSE: MOREPENLAB. Summary written with AI assistance from the document.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹120.38
- Market cap
- ₹6,596 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 46.9×Sector 50.4×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 1.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Annual General Meeting
Morepen Laboratories held its 41st Annual General Meeting on September 26, 2026, to conduct routine business, including dividend declaration and approval of director appointments.
Morepen Laboratories Other Announcement
Morepen Laboratories has been assigned an 'Adequate' ESG rating of 'CRISIL ESG 60' by Crisil ESG Ratings & Analytics Limited based on publicly disclosed information.
Morepen Laboratories Production Started
Morepen Laboratories successfully completed the first phase of its manufacturing capacity expansion. Installed reactor capacity for API and CDMO operations increased from 535 KL to 614 KL.
- reactor capacity increase
- 79.0 KL
Morepen Laboratories Annual General Meeting
Morepen Laboratories dispatched a notice to shareholders without registered emails providing the Annual Report 2025-26 weblink. The company proposed a final dividend of ₹0.20 per share.
Morepen Laboratories Annual General Meeting
Morepen Laboratories has scheduled its 41st Annual General Meeting for September 26, 2026. The board has proposed a final dividend of ₹0.20 per equity share.
- Value
- ₹197.1 Cr
Morepen Laboratories Bags ₹825 Cr Order from Leading global pharmaceutical company
Morepen Laboratories secured a multi-year CDMO mandate worth approximately ₹825 Crore from a global pharmaceutical firm. This represents one of the largest single mandates in the company's history.
- Value
- ₹825.0 Cr
- From
- Leading global pharmaceutical company
- Execution
- Multi-year